The Street Is Finally Waking Up To Crinetics Pharmaceuticals Inc (NASDAQ: CRNX)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Stocks Info

Crinetics Pharmaceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $46.81 and fluctuated between $47.16 as its day high and $44.01 as its day low. The current market capitalization of Crinetics Pharmaceuticals Inc is $3.65B. A total of 1.29 million shares were traded on the day, compared to an average of 746.42K shares.

In the most recent transaction, Knight Jeff E. sold 32,359 shares of CRNX for 44.31 per share on Mar 22 ’24. After the transaction, the Chief Operating Officer now owns 52,580 company shares. In a previous transaction on Mar 20 ’24, Fust Matthew K sold 60,000 shares at 44.14 per share. CRNX shares that Director owns now total 18,536.

Among the insiders who sold shares, Pizzuti Dana disposed of 15,089 shares on Mar 20 ’24 at a per-share price of $44.06. This resulted in the Chief Med and Dev Officer holding 27,786 shares of CRNX after the transaction. In another insider transaction, Wilson Marc sold 6,942 shares at $42.91 per share on Mar 19 ’24. Company shares held by the CFO now total 110,630.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, CRNX has a high of $47.58 and a low of $15.23.

As of this writing, CRNX has an earnings estimate of -$0.81 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of -$0.68 per share and a lower estimate of -$0.94. The company reported an EPS of -$1.01 in the last quarter, which was -17.40% lower than expectations of -$0.86.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CRNX’s latest balance sheet shows that the firm has $333.71M in Cash & Short Term Investments as of fiscal 2021. There were $3.07M in debt and $15.99M in liabilities at the time. Its Book Value Per Share was $7.91, while its Total Shareholder’s Equity was $331.94M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRNX is Buy with a score of 4.85.

Most Popular

Related Posts